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OBJECTIVES:Most thyroid diseases are nodular and have been investigated using ultrasound-guided fine needle
aspiration biopsy (FNAB), the reports of which are standardized by the Bethesda System. Bethesda category III
represents a heterogeneous group in terms of lesion characteristics and the malignancy rates reported in the
literature. The objective of the present study was to evaluate the differences in the malignancy rates among
Bethesda III subcategories.
METHODS: Data from 1,479 patients who had thyroid surgery were reviewed. In total, 1,093 patients (89.6%
female, mean age 52.7 (13-89) years) were included, and 386 patients were excluded. FNAB results (based on
Bethesda Class) and histopathological results (benign or malignant) for coincident areas were collected.
Bethesda III patients were subcategorized according to cytopathological characteristics (FLUS: follicular lesion of
undetermined significance, Bethesda IIIA; AUS: atypia of undetermined significance, Bethesda IIIB). Data were
correlated to obtain the malignancy rates for each Bethesda category and the newly defined subcategory.
RESULTS: FNAB results for these patients were as follows: Bethesda I: 3.1%; Bethesda II: 18.6%; Bethesda III:
35.0%; Bethesda IV: 22.1%; Bethesda V: 4.1%; and Bethesda VI: 17.1%. The malignancy rates for Bethesda Class
IIIB were significantly higher than those for Bethesda Class IIIA (po0.001) and Bethesda Class IV (po0.001).
Bethesda Class IIIA showed significantly lower malignancy rates than Bethesda Class III overall (po0.001)
CONCLUSIONS: Improvements of the Bethesda System should consider this subcategorization to better reflect
different malignancy rates, which may have a significant impact on the decision-making process.
KEYWORDS: Thyroid; Ultrasound; Fine Needle Aspiration Biopsy; Bethesda.
’ INTRODUCTION
Most thyroid diseases occur in a nodular form and can
reach a prevalence of up to 68% in adult women (1).
Although most of these nodules are benign, the possibility of
malignancy is a major concern. During 2017, more than 7,000
patients were diagnosed with thyroid cancer in Brazil,
according to the National Institute of Cancer José Alencar
Gomes da Silva (INCA) (2).
Ultrasound-guided fine needle aspiration biopsy (FNAB)
is one of the most important tools to investigate thyroid
nodules (3,4), and since 2009, FNAB reports have been stan-
dardized by the Bethesda System for Reporting Thyroid
Cytopathology (5,6) (here referred only as Bethesda). Appro-
ximately 60% of all biopsied nodules are reported as benign,
10% present definitive criteria for malignancies, and 30%
cannot be defined using only their cytological features (7).
Bethesda class III is an important group that fits most of
these undefined cases, and it is a heterogeneous category that
includes nodules classified as a follicular lesion of undeter-
mined significance (FLUS) or an atypia of undetermined
significance (AUS). The expected malignancy rates for the
Bethesda III category range from 5 to 15% according to
relevant published studies (5). However, some recent papers
have shown higher malignancy rates associated with AUSs
(8-10), suggesting that the heterogeneity of lesions within
this class may have relevant impacts on the diagnosis and
management of patients.
The aim of this study was to evaluate the malignancy rates in
two subcategories of Bethesda III at reference centers in Brazil.
’ MATERIALS AND METHODS
The present study was approved by the institutional review
board (CAPPESQ).
This retrospective study included 1,479 patients who under-
went thyroidectomy at two university hospitals of the Uni-
versity of Sao Paulo Medical School (Hospital das Clínicas
[HCFMUSP] and Instituto do Cancer do Estado de São PauloDOI: 10.6061/clinics/2018/e370
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[ICESP]), between September 2009 and April 2013. The study
included a detailed review of clinical information from
patients’ hospital files, as well as from pathological samples
(surgical specimens and FNAB slides) and pathological
reports for all cases.
In order to better characterize this subset of patients in
comparison to all patients undergoing FNAB in our centers
(not only those that underwent thyroidectomy), we also
reviewed all of the 4010 thyroid FNAB reports produced
during the same period.
For thyroidectomy patients, the inclusion criteria were
as follows: (A) patients whose preoperative examinations,
surgery and post-operative evaluations were all performed
in the aforementioned institutions and (B) the availability of
FNAB material for review. A flowchart depicting subject
enrollment in this study according to the inclusion/exclusion
criteria is presented in Figure 1.
From the 1,479 patients who underwent thyroidectomy,
we excluded 386 patients (248 patients due to lack of repor-
ted patient data standardization and 138 due to the absence
of a definitive match between the FNAB area and the post-
operative tissue samples). Finally, there were 1,093 patients
eligible for the study. Patients’ files were reviewed by
the medical team according to established standards of the
Institutional Review Board (Ethics Committee), and reported
FNAB data and final histological diagnoses were collected.
When more than one biopsy was performed, the one higher
with a Bethesda Class (higher malignancy risk) was con-
sidered for this study. We took extra care to specifically
correlate the biopsied nodule to the final histological report
(to compare the same reported areas), and the pathologists
reviewing the histopathological report were blinded to the
FNAB results and vice-versa.
Fine needle aspiration biopsy reports, as well as final histo-
pathological reports from each patient, were reviewed and
correlated to the corresponding tissue region and nodule.
Patients diagnosed as Bethesda III were subdivided into two
groups according to the cytological characteristics: Bethesda
IIIA (FLUS) and Bethesda IIIB (AUS).
FLUSs were characterized by a small follicular pattern
with poorly attached cells and a small amount of colloid.
AUSs were characterized by the presence of cellular and
nuclear atypias, regardless of the distribution pattern of
the cells, which could be follicular, papillary or non-
characteristic (5).
All of the patients underwent surgery for the classical
indications of thyroidectomy (substernal goiter, compression,
suspicious or confirmation of malignancy and hyperthyroid-
ism of difficult clinical control).
Comparisons between malignancy rates in different cate-
gories were performed using chi-squared and Fisher’s exact
tests. Descriptive and statistical analyses were performed
using SPSS 20 software (2011; IBM Corp, USA).
’ RESULTS
There were 4,010 FNABs performed in our hospitals during
the studied period. The frequency of each Bethesda Class
was as follows: Bethesda I: 11.5% (463); Bethesda II: 62.0%
(2481); Bethesda III: 13.2% (530); Bethesda IV: 4.7% (190);
Bethesda V: 1.5% (62); and Bethesda VI: 7.1% (284) (Figure 2).
For the FNAB–thyroidectomy correlation and Bethesda III
subcategorization, we included 1,093 patients who met the
aforementioned inclusion and exclusion criteria. The studied
population included 979 (89.6%) female patients. The mean
age was 52.7 years (range: 13-89).
Figure 1 - Schematic representation of the study design and patient inclusion/exclusion criteria.
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The FNAB results within these 1,093 cases included the
following classifications: Bethesda I: 3.1% (34); Bethesda II:
18.6% (204); Bethesda III: 35.0% (384); Bethesda IV: 22.1%
(242); Bethesda V: 4.1% (42); and Bethesda VI: 17.1% (187)
(Figure 2).
The malignancy rates of the biopsied nodules as a function
of Bethesda category are shown in Table 1.
The 384 subjects classified as Bethesda III were subcate-
gorized according to histological results as Bethesda IIIA
(FLUS) and IIIB (AUS). The malignancy rate for the 269
subjects classified as Bethesda IIIA (FLUS) was 5.6%, and
the rate for the 115 subjects classified as Bethesda IIIB (AUS)
was 27%. The absolute difference in the malignancy rates
between the Bethesda IIIA and IIIB categories was 21.4%
(95% CI 13-30) (Table 2). The absolute difference in the
malignancy rates between the Bethesda IIIB subcategory
(27%) and Bethesda IV subcategory (11.2%) was 16% (95%
CI 7-25).
The distributions of the histopathological results in the
patients undergoing operation according to FNAB subcate-
gories are presented in Table 2. The malignancy rates for
Bethesda IIIB were significantly higher than for Bethesda
IIIA (po0.001) and Bethesda IV (po0.001) (Table 2). Bethesda
IIIA cases had significantly lower malignancy rates than
Bethesda III cases overall (po0.001).
’ DISCUSSION
Here, we present the association between FNAB and histo-
pathological results in 1,093 patients who underwent thyroid-
ectomy. We demonstrate that the malignancy rates within
Bethesda Class III are heterogeneous and that these malig-
nancy rates are significantly higher for Bethesda Class IIIB
(AUS) than for Bethesda Class IIIA (FLUS).
In the Bethesda Classification System for Thyroid Lesions,
Bethesda III is the most heterogeneous category because it
merges follicular lesions without nuclear atypia (i.e., FLUSs)
and lesions with nuclear atypia both in a follicular or a non-
follicular pattern (i.e., AUSs). This combination obviously
makes the lesions easy to classify as Class III, but it can also
create a broad spectrum of diagnoses with different out-
comes, which may make reaching a clinical decision difficult.
Therefore, we chose to divide this category into two
subcategories: (1) Bethesda IIIA: FLUS and (2) Bethesda IIIB:
AUS. The goal of this subcategorization was to demonstrate
that the Bethesda III classification is very heterogeneous but
that some of its characteristics and patterns can still be
clearly defined on cytological smears and are related to a
higher or lower risk of malignancy. These characteristics can
thus be used to narrow the diagnostic spectrum and facilitate
clearer and more cost-effective clinical decisions (8).
Figure 2 - Distribution of Bethesda Classifications in FNAB reports in all patients and in the surgically treated patients.
Table 1 - Malignancy rates of biopsied nodules as a function of
Bethesda category.
FNAB Benign Malignant Cases
Bethesda I 94.1% 5.9% 34
Bethesda II 98.5% 1.5% 204
Bethesda III 88% 12% 384
Bethesda IV 88.8% 11.2% 242
Bethesda V 26.2% 73.8% 42
Bethesda VI 1.1% 98.9% 187
Table 2 - Malignancy rates of related biopsied nodule as a
function of Bethesda III subcategory.
Benign Malignant Cases
Bethesda III (overall) 88% 12% 384
Bethesda IIIA 94.4%a 5.6%a 269
Bethesda IIIB 73%b 27%b 115
Bethesda IV 88.8% 11.2% 242
apo0.001 compared with III (overall).
bpo0.001 compared with IIIA and IV.
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Since the implementation of the Bethesda System, there
has been a decrease in non-diagnostic FNAB reports, which
have become more accurate in providing descriptive inter-
pretations of cytological findings (11). The FNA sensitivity
reported in the literature varies from 65 to 99%, and its
specificity varies from 72 to 100%. These values are strongly
dependent on examiner experience and other technical
details (12-14).
One of the most important features of the Bethesda System
was the creation of Class III. This heterogeneous category
includes cases that are neither clearly benign nor sufficiently
characteristic to be classified into either of the two fol-
lowing categories: IV (follicular neoplasm or suspicious for
follicular neoplasm) or V (suspicious for malignancy) (15). It
involves some subjectivity, reflecting the difficulty in cyto-
logically diagnosing follicular lesions, and this subjectivity is
strongly associated with the interpretation of the pathologist
(16,17).
The expected malignancy rate for Bethesda Class III ranges
from 5 to 15% according to relevant studies (5). However,
the actual malignancy rate in this subcategory, usually con-
firmed by histopathology, is very difficult to determine when
not treated via surgery. In our study, the malignancy rate for
Bethesda Class III was 12%, matching the previously expec-
ted malignancy rate.
Some studies have divided Bethesda III in two categories
as follows: (a) cases presenting common characteristics of
papillary carcinomas and (b) cases without features of papil-
lary carcinoma. This study showed increased malignancy
rates associated with the papillary features. (5). Another
study from Renshaw subdivided Bethesda III in 4 groups,
and found a difference in the malignancy risks between two
of them; the group with papillary carcinoma characteristics
had a 38% higher risk of malignancy (18).
Recently, other authors have divided Bethesda III nodules
into those with low cellularity with a microfollicular pattern
and those showing nuclear atypia, and some studies have
suggested that nuclear atypia is an independent risk factor.
Kelman et al. found that up to 60% of thyroid nodules with
nuclear atypia were related to malignant disease, while only
7% of those without atypia had the same diagnosis (19,20).
Other authors have evaluated the subclassification of
Bethesda III in the following two categories: architectural
atypia and nuclear atypia. Gan et al. (9) showed that patients
with nuclear atypia had a malignancy rate of 35% compared
to a rate of 10% for other Bethesda III cases. Similarly, Shrestha
et al. (10) showed a 36.8% malignancy rate for patients with
nuclear atypia compared to rate of 10.8% in those without
nuclear atypia. Another recent study from Brazil, analyzing
results from second FNABs in patients with a prior Bethesda
III diagnosis showed a malignancy rate of 41.5% in patients
with nuclear atypia, while those with architectural atypia had
a malignancy rate of 15.5% (21).
In our study, we found a malignancy rate of 27% for
Bethesda IIIB cases, which is lower than the observed
malignancy rates for cases with nuclear atypia in previous
studies. We also found a malignancy rate of 5.6% for Bethesda
IIIA cases, which is also lower than the rates observed for
published cases of architectural atypia. One possible explana-
tion for these lower rates, which is also a unique aspect of this
study, is the fact that we took special care to correlate FNAB
results with the tissue sample of the same biopsied nodule,
without considering the diagnosis in the whole post-operative
specimen.
Interestingly our malignancy rates for Bethesda IIIB were
higher than the upper expected limit for Bethesda III in the
literature (15%). Additionally, this rate was significantly
higher than the malignancy rates expected for Bethesda IV
in the literature (8) and the rate the observed for our own
Bethesda IV cases (11.2%).
Several authors have demonstrated the heterogeneity
of Bethesda Class III. The subcategorization criteria and
nomenclature vary, but in the end, they all lead to the same
key message: Malignancy rates can be associated with certain
patterns. In this study, we preferred to use the nomenclature
IIIA and IIIB for two reasons: (1) we believe the single letters
better fit the numbers used for Bethesda (instead of including
the acronyms) and (2) it leaves room for future developments
to include in the same subcategory (A or B) all the relevant
features (architectural organization, nuclear atypia, cytoplasm
alteration, etc.) that proved to be related to increased mali-
gnancy rates, thus helping to standardize diagnoses and
reports.
In conclusion, the higher malignancy rates systematically
observed in cases with nuclear atypia and its related features
demonstrate that improvements in the Bethesda System for
thyroid FNAB reports should consider the subcategorization
of Class III in order to better reflect these differences and
positively impact the decision-making process for further
diagnostic tests and/or treatment selection.
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